Cargando…
The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
Background: Clinical management of ischemic events and prevention of vascular disease is based on antiplatelet drugs. Given the relevance of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) as a candidate target in thrombosis, the main goal of the present study was to identify novel antiplatele...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037016/ https://www.ncbi.nlm.nih.gov/pubmed/33804911 http://dx.doi.org/10.3390/ijms22073304 |
_version_ | 1783677045131182080 |
---|---|
author | Barrachina, María N. Izquierdo, Irene Hermida-Nogueira, Lidia Morán, Luis A. Pérez, Amparo Arroyo, Ana B. García-Barberá, Nuria González-Conejero, Rocío Troitiño, Sara Eble, Johannes A. Rivera, José Martínez, Constantino Loza, María I. Domínguez, Eduardo García, Ángel |
author_facet | Barrachina, María N. Izquierdo, Irene Hermida-Nogueira, Lidia Morán, Luis A. Pérez, Amparo Arroyo, Ana B. García-Barberá, Nuria González-Conejero, Rocío Troitiño, Sara Eble, Johannes A. Rivera, José Martínez, Constantino Loza, María I. Domínguez, Eduardo García, Ángel |
author_sort | Barrachina, María N. |
collection | PubMed |
description | Background: Clinical management of ischemic events and prevention of vascular disease is based on antiplatelet drugs. Given the relevance of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) as a candidate target in thrombosis, the main goal of the present study was to identify novel antiplatelet agents within the existing inhibitors blocking PI3K isoforms. Methods: We performed a biological evaluation of the pharmacological activity of PI3K inhibitors in platelets. The effect of the inhibitors was evaluated in intracellular calcium release and platelet functional assays, the latter including aggregation, adhesion, and viability assays. The in vivo drug antithrombotic potential was assessed in mice undergoing chemically induced arterial occlusion, and the associated hemorrhagic risk evaluated by measuring the tail bleeding time. Results: We show that PI3K Class IA inhibitors potently block calcium mobilization in human platelets. The PI3K p110δ inhibitor Idelalisib inhibits platelet aggregation mediated by ITAM receptors GPVI and CLEC-2, preferentially by the former. Moreover, Idelalisib also inhibits platelet adhesion and aggregation under shear and adhesion to collagen. Interestingly, an antithrombotic effect was observed in mice treated with Idelalisib, with mild bleeding effects at high doses of the drug. Conclusion: Idelalisib may have antiplatelet effects with minor bleeding effects, which provides a rationale to evaluate its antithrombotic efficacy in humans. |
format | Online Article Text |
id | pubmed-8037016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80370162021-04-12 The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential Barrachina, María N. Izquierdo, Irene Hermida-Nogueira, Lidia Morán, Luis A. Pérez, Amparo Arroyo, Ana B. García-Barberá, Nuria González-Conejero, Rocío Troitiño, Sara Eble, Johannes A. Rivera, José Martínez, Constantino Loza, María I. Domínguez, Eduardo García, Ángel Int J Mol Sci Article Background: Clinical management of ischemic events and prevention of vascular disease is based on antiplatelet drugs. Given the relevance of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) as a candidate target in thrombosis, the main goal of the present study was to identify novel antiplatelet agents within the existing inhibitors blocking PI3K isoforms. Methods: We performed a biological evaluation of the pharmacological activity of PI3K inhibitors in platelets. The effect of the inhibitors was evaluated in intracellular calcium release and platelet functional assays, the latter including aggregation, adhesion, and viability assays. The in vivo drug antithrombotic potential was assessed in mice undergoing chemically induced arterial occlusion, and the associated hemorrhagic risk evaluated by measuring the tail bleeding time. Results: We show that PI3K Class IA inhibitors potently block calcium mobilization in human platelets. The PI3K p110δ inhibitor Idelalisib inhibits platelet aggregation mediated by ITAM receptors GPVI and CLEC-2, preferentially by the former. Moreover, Idelalisib also inhibits platelet adhesion and aggregation under shear and adhesion to collagen. Interestingly, an antithrombotic effect was observed in mice treated with Idelalisib, with mild bleeding effects at high doses of the drug. Conclusion: Idelalisib may have antiplatelet effects with minor bleeding effects, which provides a rationale to evaluate its antithrombotic efficacy in humans. MDPI 2021-03-24 /pmc/articles/PMC8037016/ /pubmed/33804911 http://dx.doi.org/10.3390/ijms22073304 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Barrachina, María N. Izquierdo, Irene Hermida-Nogueira, Lidia Morán, Luis A. Pérez, Amparo Arroyo, Ana B. García-Barberá, Nuria González-Conejero, Rocío Troitiño, Sara Eble, Johannes A. Rivera, José Martínez, Constantino Loza, María I. Domínguez, Eduardo García, Ángel The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title | The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title_full | The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title_fullStr | The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title_full_unstemmed | The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title_short | The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential |
title_sort | pi3kδ inhibitor idelalisib diminishes platelet function and shows antithrombotic potential |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037016/ https://www.ncbi.nlm.nih.gov/pubmed/33804911 http://dx.doi.org/10.3390/ijms22073304 |
work_keys_str_mv | AT barrachinamarian thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT izquierdoirene thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT hermidanogueiralidia thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT moranluisa thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT perezamparo thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT arroyoanab thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT garciabarberanuria thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT gonzalezconejerorocio thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT troitinosara thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT eblejohannesa thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT riverajose thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT martinezconstantino thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT lozamariai thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT dominguezeduardo thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT garciaangel thepi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT barrachinamarian pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT izquierdoirene pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT hermidanogueiralidia pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT moranluisa pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT perezamparo pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT arroyoanab pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT garciabarberanuria pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT gonzalezconejerorocio pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT troitinosara pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT eblejohannesa pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT riverajose pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT martinezconstantino pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT lozamariai pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT dominguezeduardo pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential AT garciaangel pi3kdinhibitoridelalisibdiminishesplateletfunctionandshowsantithromboticpotential |